FYINeuren Pharmaceuticals (ASX: NEU) Analyst Updates - Feb 26,...

FYI

Neuren Pharmaceuticals (ASX: NEU) Analyst Updates - Feb 26, 2025

Current Price: ~AU$13.04

| Analyst/Firm | **Target Price** | Rating | Date | Upside | Notes |

| J.P. Morgan | **AU$22.00** | Overweight | Late 2024 | ~62% | Cut from $26.70, still sees Daybue upside |

| TipRanks Consensus | **AU$31.03** | Moderate Buy | Last 3 months | ~129% | Avg of 2; high $32.75, low $29.30 |

| Bell Potter | **AU$27.00** | Buy | Jan 2025 | ~99% | Loves Daybue U.S. sales & pipeline |

| NURPF OTC Consensus | **AU$29.62** | Strong Buy | Last 3 months | ~118% | 5 analysts; high $33.14, low $25.48 |

| Wilsons | **AU$25.00** | Overweight | Mid-2024 | ~84% | Older but solid on rare disease focus |

| Simply Wall St | **AU$29.00** | N/A | Feb 2025 | ~114% | DCF estimate, 15.7% growth assumed |

| TradingView | **AU$24.97** | Buy | Feb 2025 | ~84% | Max $30.94, min $19.00, broad consensus |

| Morningstar | **N/A** | N/A | Recent | N/A | No target, but likes growth potential |

More updates post-Acadia’s earnings call tomorrow (Feb 27 AEDT)!

For information purposes only - do your own research